Esperion Therapeutics, Inc. ESPR

About Esperion Therapeutics, Inc. (ESPR): stock profile, AI score and financials

Acquired by Essence Parent Inc.: Esperion Therapeutics, Inc. (ESPR) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on July 13, 2026 (SEC 8-K 2.01). Its last closing price was on July 10, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Esperion Therapeutics, Inc. (ESPR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks ESPR using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), Esperion Therapeutics, Inc. reports quarterly revenue of $80.1M, net income of $-25.2M, an operating margin of -8.2%. Top institutional holders of ESPR by reported 13-F value include GLAZER CAPITAL, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ESPR trades on the Nasdaq exchange and files with the SEC under CIK 1434868. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Esperion Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Mar 31, 2026SEC EDGAR: CIK 1434868 →